RUTHFULLY YOURS

https://spectator.us/covid-statistics-politics-other-means/

Statistics is the continuation of politics by other means, to misquote Clausewitz. One hundred and fifty years after the crushing of the revolutionary Paris Commune, historians still clash aggressively about the death toll. Was it as high as 40,000 or as low as 10,000?

It matters because the Paris Commune is a shibboleth, a great left-wing site of memory and martyrdom, made famous by Karl Marx’s pamphlet The Civil War in France. He presented the Paris Commune as the first great experiment in communist government. Its crushing by the army of the conservative Adolphe Thiers is depicted in left-wing folk memory as the ‘reactionary, repressive forces of capitalism’ ending an idyllic experiment in socialism. So for martyrdom’s sake it is better to put the number ‘slaughtered’ at 40,000 rather than 10,000. And historians go to great lengths to adduce statistical evidence in one direction or another.

In the 1960s demographers revealed that the Soviet government stopped publishing its statistics on life expectancy because they were not progressing as fast as in the West. Today Chinese GDP growth statistics are widely viewed as manipulated. COVID-19 pandemic statistics have inevitably become political too. As the Cambridge statistician Prof David Spiegelhalter wrote in the Guardian on April 30, ‘people are not so interested in the numbers themselves — they want to say why they are so high, and ascribe blame.’ And why do they want to ascribe blame? Because other political agendas have not been laid to rest.

And so COVID statistics are the continuation of politics by other means. The relish with which certain international media highlight the death toll in the US, for example, is a rather transparent attack on Donald Trump, especially when they fail to adjust deaths to 100,000 population.

The otherwise authoritative left-of-center French daily Le Monde for example refers to the United States ‘as the most affected [country] as much in number of deaths (67,682) as in cases (1.15 million)’ but fails to account for population, which puts the US around 10th in the world.

Don’t blame big pharma…blame the big stockholders in Gilead Bill -Gates and George Soros and their media pet Dr. Anthony Faulti………rsk

Gilead’s Remdesivir is getting a lot of praise from the NIH, while the much cheaper hydroxychloroquine is getting a cold reception. Wonder why.

When President Trump brought up hydroxychloroquine as a promising potential treatment for COVID-19, a huge upsurge of negative political publicity followed from it.  It was strange stuff, because up until then, the treatment, which had been safely used to treat malaria, lupus, and arthritis, had been seeing promising results for COVID-19, too.  Yet the condemnations from all sides poured for weeks.  It wasn’t just the political establishment blasting it; it seemed to be the medical establishment, too.  That raises questions as to whether financial interests might be involved here.

It started with the press engaging in its customary contrarianism against Trump when he called the treatment “promising.”  The logic was simple: If Trump liked it, then it had to be bad.

How’s this for a slanted headline and report from NPR, which ran on April 10?

COVID-19 Patients Given Unproven Drug In Texas Nursing Home In ‘Disconcerting’ Move

https://www.sciencedaily.com/releases/2020/05/200504074722.htm
Source:
Utrecht University
Summary:
Researchers report that they have identified a fully human monoclonal antibody that prevents the SARS-CoV-2 (COVID-19) virus from infecting cultured cells. The discovery is an initial step towards developing a fully human antibody to treat or prevent the respiratory disease COVID-19 caused by the novel coronavirus SARS-CoV-2.

Researchers at Utrecht University, Erasmus Medical Center and Harbour BioMed (HBM) today reported that they have identified a fully human monoclonal antibody that prevents the SARS-CoV-2 (COVID-19) virus from infecting cultured cells. The discovery, published online today in Nature Communications, is an initial step towards developing a fully human antibody to treat or prevent the respiratory disease COVID-19 caused by the novel coronavirus SARS-CoV-2.

The COVID-19 pandemic has spread rapidly across the globe infecting more than 3.3M people worldwide and killing more than 235,000 people so far.

“This research builds on the work our groups have done in the past on antibodies targeting the SARS-CoV that emerged in 2002/2003,” said Berend-Jan Bosch, Associate Professor, Research leader at Utrecht University, and co-lead author of the Nature Communications study. “Using this collection of SARS-CoV antibodies, we identified an antibody that also neutralizes infection of SARS-CoV-2 in cultured cells. Such a neutralizing antibody has potential to alter the course of infection in the infected host, support virus clearance or protect an uninfected individual that is exposed to the virus.”